title: [Docetaxel in combination with epirubicin as the first-line chemotherapy for advanced and recurrent breast cancer: a multicenter phase II study].
abstract: This study examined the efficacy and tolerability of docetaxel(DOC)in combination with epirubicin(EPI)as the first-line treatment for patients with advanced and recurrent breast cancer. A total of 56 female patients with metastatic breast cancer not previously treated for metastatic disease received DOC(60mg/m²)and EPI(60mg/m2)on day 1 every 3 weeks. The patient characteristics included a median age of 53 years. Advanced disease was present in 86% of patients, and recurrent disease was found in 14%; 3 or more metastatic sites had been diagnosed in 38% of patients, and 59% patients were ER+. The median number of courses administered was 6. The median dose intensity was 18. 7mg/m²week for DOC and EPI, and the relative dose intensities were 93. 5%and 93. 3%, respectively. The clinical responses included a complete response in 5%, a partial response in 54%, and stable disease in 33% of patients, with a disease control rate of 92%. The progression-free survival was 78. 3%, and the overall survival was 91. 9% at 1 year. Grade 3/4 toxicities included neutropenia in 82%, leukopenia in 71%, febrile neutropenia in 16%, anorexia in 9%, and anemia in 7%of the patients. Neither congestive heart failure nor toxic death occurred. The D and E combination with doses of 60mg/m2 is an active and generally well-tolerated regimen that can be used as first-line chemotherapy for patients with metastatic breast cancer.
authors.forename: Keisei
authors.initials: K
authors.lastname: Anan
authors.forename: Maki
authors.initials: M
authors.lastname: Tanaka
authors.forename: Shoshu
authors.initials: S
authors.lastname: Mitsuyama
authors.forename: Shigeru
authors.initials: S
authors.lastname: Imamura
authors.forename: Shinji
authors.initials: S
authors.lastname: Ohno
authors.forename: Shinsuke
authors.initials: S
authors.lastname: Hara
authors.forename: Tatsuji
authors.initials: T
authors.lastname: Oikawa
authors.forename: Teruhiko
authors.initials: T
authors.lastname: Fujii
authors.forename: Reiki
authors.initials: R
authors.lastname: Nishimura
authors.forename: Emi
authors.initials: E
authors.lastname: Ishikawa
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Yano
authors.forename: Hideki
authors.initials: H
authors.lastname: Taniguchi
authors.forename: Masayuki
authors.initials: M
authors.lastname: Ohkido
authors.forename: Tetsufumi
authors.initials: T
authors.lastname: Ohchi
authors.forename: Kazuo
authors.initials: K
authors.lastname: Chijiiwa
authors.forename: Ichirou
authors.initials: I
authors.lastname: Arime
authors.forename: Kazuo
authors.initials: K
authors.lastname: Shimada
authors.forename: Hiromichi
authors.initials: H
authors.lastname: Inoue
authors.forename: Kazuo
authors.initials: K
authors.lastname: Tamura
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D000077143:Docetaxel; D015251:Epirubicin / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D008875:Middle Aged; D009362:Neoplasm Metastasis / Q000188:drug therapy; D012008:Recurrence; D043823:Taxoids / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D043823:Taxoids; D000077143:Docetaxel; D015251:Epirubicin